Interferon-alpha for maintenance of remission in Churg-Strauss syndrome: A long-term observational study

Clinical and Experimental Rheumatology

Volumn 28, Issue 1 SUPPL. 57, 2010, Pages

  Metzler, Claudia ^a   Csernok, Elena ^b   Gross, Wolfgang L ^b   Hellmich, Bernhard ^c  

^a Krankenhaus der Barmherzigen Bruder   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c Medizinische Klinik   (Germany)

Author keywords

Churg Strauss syndrome; Interferon alpha; Relapse; Remission

Indexed keywords

ALPHA INTERFERON; ANTIINFECTIVE AGENT; AZATHIOPRINE; CYCLOPHOSPHAMIDE; DRUG ANTIBODY; GLUCOCORTICOID; LEFLUNOMIDE; METHOTREXATE; PARACETAMOL; PREDNISOLONE; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; C REACTIVE PROTEIN; CREATININE; LIVER ENZYME; ALPHA2B INTERFERON; ANTIBODY; IMMUNOLOGIC FACTOR;

ABSCESS; ADULT; ARTICLE; ASTHMA; AUTOIMMUNE THYROIDITIS; BACTERIAL INFECTION; BRONCHITIS; CEREBRAL LEUKOENCEPHALOPATHY; CHURG STRAUSS SYNDROME; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DEATH; DEPRESSION; DISEASE DURATION; DISEASE EXACERBATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EOSINOPHIL COUNT; FEMALE; FOLLOW UP; HERPES ZOSTER; HUMAN; HYPOTHYROIDISM; LARYNGITIS; LEUKOENCEPHALOPATHY; LEUKOPENIA; LOW DRUG DOSE; MALE; MYCOSIS; OBSERVATIONAL STUDY; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELAPSE; REMISSION; RESPIRATORY TRACT INFECTION; SINUSITIS; SURVIVAL; THRUSH; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VIRUS INFECTION; ACUTE RESPIRATORY FAILURE; ASEPTIC ABSCESS; BLOOD OXYGEN TENSION; CAUSE OF DEATH; COHORT ANALYSIS; DRUG DOSE ESCALATION; ECHOCARDIOGRAPHY; ERYTHROCYTE SEDIMENTATION RATE; HEART VENTRICLE ARRHYTHMIA; HOSPITALIZATION; HUMAN TISSUE; INCIDENCE; INFECTION; LONG TERM CARE; LUNG FUNCTION; LUNG INFILTRATE; LUNG LAVAGE; MAINTENANCE THERAPY; MIDDLE AGED; MONOTHERAPY; NEPHRITIS; PERICARDITIS; PREVALENCE; RESPIRATORY FAILURE; SIDE EFFECT; URINALYSIS; BLOOD; DISEASE FREE SURVIVAL; EPIDEMIOLOGY; IMMUNOLOGY; RECURRENT DISEASE;

ADULT; ANTIBODIES; CHURG-STRAUSS SYNDROME; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; REMISSION INDUCTION; SEROEPIDEMIOLOGIC STUDIES;

EID: 77954591017     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. KEOGH, KA, SPECKS U: Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am J Med 2003; 115: 284-90.
2. HELLMICH B, EHLERS S, CSERNOK E, GROSS WL: Update on the pathogenesis of Churg-Strauss syndrome. Clin Exp Rheumatol 2003; 21(Suppl. 32): S69-77.
3. SINICO RA, DI TOMA L, MAGGIORE U et al.: Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum 2005; 52: 2926-35.
4. SABLÉ-FOURTASSOU R, COHEN P, MAHR A et al. and the FRENCH VASCULITIS STUDY GROUP: Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med 2005; 143: 632-8.
5. GUILLEVIN L, FAIN O, LHOTE F et al.: Lack of superiority of steroids plus plasma exchange to steroids alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome. A prospective, randomized trial in 78 patients. Arthritis Rheum 1992; 35: 208-15.
6. HELLMICH B, GROSS WL: Recent progress in the pharmacotherapy of Churg-Strauss syndrome. Expert Opin Pharmacother 2004; 5: 25-35.
7. GUILLEVIN L, LHOTE F, GAYRAUD M: Prognostic factors in polyarteriitis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine1996; 75: 17-28.
8. GUILLEVIN L, COHEN P, GAYRAUD M. LHOTE F. JARROUSSE B, CASASSUS P: Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 1999; 78: 26-37.
9. BOURGARIT A, LE TOUMELIN P, PAGNOUX C et al. and the FRENCH VASCULITIS STUDY GROUP: Deaths occurring during the first year after treatment onset for polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: a retrospective analysis of causes and factors predictive of mortality based on 595 patients. Medicine (Baltimore) 2005; 84: 323-30.
10. PHILLIP R, LUQMANI R: Mortality in systemic vasculitis: a systematic review Clin Exp Rheumatol 2008; 26 (Suppl. 51 ): S94-S104.
11. GAYRAUD M, GUILLEVIN L, LE TOUMELIN P et al.: Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and ChurgStrauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum 2001; 44: 666-75.
12. REINHOLD-KELLER E, HERLYN K, WAGNER-BASTMEYER R et al.: No difference in the incidences of vasculitides between north and south Germany: first results of the German vasculitis register. Rheumatology 2002; 41: 540-9.
13. TALAR-WILLIAMS C, HIJAZI YM, WALTHER MM et al.: 1996. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener's granulomatosis. Ann Intern Med 1996; 124: 477-84.
14. GAYRAUD M, GUILLEVIN L, COHEN P et al.: Treatment of good-prognosis polyarteritis nodosa and Churg-Strauss syndrome: comparison of steroids and oral or pulse cyclophosphamide in 25 patients. French Cooperative Study Group for Vasculitides. Br J Rheumatol 1997; 36: 1290-7.
15. METZLER C, HELLMICH B, GAUSE A, GROSS WL. DE GROOT K: Churg Strauss-syndrome - successful induction of remission with methotrexate and unexpected high cardiac and pulmonary relapse ratio during maintenance treatment. Clin Exp Rheumatol 2004; 22(Suppl. 36):S52-61.
16. TATSIS E. SCHNABELA, GROSS WL: Interferon-alpha treatment of four patients with the Churg-Strauss syndrome. Ann Intern Med 1998; 129: 370-4.
17. REISSIG A, FÖRSTER M, MOCK B, SCHILDER C, KROEGEL C: Interferon-alpha treatment of the Churg-Strauss syndrome. Dtsch Med Wochenschr. 2003; 128: 1475-8.
18. TERMEER CC, SIMON JC, SCHÖPF E: Low-dose interferon alfa-2b for the treatment of Churg-Strauss syndrome with prominent skin involvement. Arch Dermatol 2001; 137: 136-8.
19. LESENS O, HANSMANN Y, NERSON J et al.: Severe Churg-Strauss syndrome with mediastinal lymphadenopathy treated with interferon therapy. Eur J Intern Med 2002; 13: 458.
20. METZLER C, SCHNABEL A, GROSS WL, HELLMICH B: A phase II study of interferon-alpha for the treatment of refractory Churg-Strauss syndrome. Clin Exp Rheumatol 2008; 26 (Suppl. 49): S35-S40.
21. MASI AT, HUNDER GG, LIE JT et al.: The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 1990; 33: 1094-100.
22. LUQMANI R: Evaluation of vasculitis disease activity in Europe. Eur J Intern Med 2001; 12: 401-2.
23. DE GROOT K, GROSS WL, HERLYN K, REINHOLD-KELLER E: Development and validation of a disease extent index for Wegener's granulomatosis. Clin. Nephrol 2001; 55: 31-8.
24. ANTONELLI G, GIANNELLi G, CURRENTI M et al.: Antibodies to interferon (IFN) in hepatitis C patients relapsing while continuing recombinant IFN-alpha2 therapy. Clin Exp Immunol 1996; 104: 384-7.
25. BONETTI P, DIODATI G, DRAGO C et al.: Interferon antibodies in patients with chronic hepatitic C virus infection treated with recombinant interferon alpha-2 alpha. J Hepatol 1994; 20: 416-20.
26. METZLER C, LAMPRECHT P, HELLMICH B, REUTER M, ARLT AC, GROSS WL: Leukoencephalopathy after treatment of Churg-Strauss-Syndrome with interferon-alpha. Ann Rheum Dis 2005; 64: 1242-3.
27. SOLANS R, BOSCH JA, PEREZ-BOCANEGRA C et al.: Churg-Strauss syndrome: outcome and long-term follow-up of 32 patients. Rheumatology 2001; 40: 763-71.
28. SHTALRID M, LUGASSY G, ROSENSAFT J, BERREBI A: Treatment of chronic myeloid leukemia with interferon alpha (Roferon): results of the Israeli Study Group on CML. Leuk Lymphoma 1993; 11 (Suppl. 1): 193-7.
29. STEIS RG, SMITH JW 2ND, URBA WJ et al.: Resistance to recombinant interferon alfa-2a in hairy-cell leukemia associated with neutralizing anti-interferon antibodies. N Engl J Med 1988; 318: 1409-13.
30. RONNBLOM LE, JANSON ET, PERERS A, OBERG KE, ALM GV: Characterization of anti-interferon-alpha antibodies appearing during recombinant interferon-alpha 2a treatment. Clin Exp Immunol 1992; 89: 330-5.
31. KIENE M, CSERNOK E, MÜLLER A, METZLER C, TRABANDT A, GROSS WL: Elevated interleukin-4 and interleukin-13 production by T cell lines from patients with Churg-Strauss syndrome. Arthritis Rheum 2001; 44: 469-73.
32. SCHANDENE L, DEL PRETE GF, COGAN E et ai: Recombinant interferon-alpha selectively inhibits the production of interleukin-5 by human CD4+ T Cells. J Clinical Invest 1996; 97: 309-15.
33. ROTHENBERG ME, KLION AD, ROUFOSSE FE et al., and the MEPOLIZUMAB HES STUDY GROUP: Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 2008; 358: 1215-28.